Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007

TUCSON, Ariz., March 31 /PRNewswire/ -- ImaRx Therapeutics, Inc., a biopharmaceutical company developing and commercializing therapies for vascular disorders, today provided a corporate update along with fourth quarter and full year 2007 financial results.

2007 Year in Review:

-- Initiated TUCSON Phase I/II clinical study

-- Received FDA approval to market urokinase under new trade name


-- Signed strategic licensing agreement with Bracco International

-- Completed Initial Public Offering

-- Awarded Phase I STTR grant from the National Institutes of Health

-- Signed research collaboration with Royal Philips Electronics

-- Extended expiration dating of urokinase product inventory

Key Corporate Highlights:

PhaseI/II TUCSON Clinical Trial and SonoLysis Program Update

In January of 2007, the Company initiated its TUCSON trial, a Phase I/II clinical study designed to assess the safety of the Company's proprietary MRX- 801 microbubbles in combination with ultrasound and tPA in ischemic stroke patients. The TUCSON trial was designed with four 18-patient cohorts to evaluate increasing doses of MRX-801. In the second dose cohort, the Company observed a greater number of reported symptomatic intracranial hemorrhages in subjects receiving treatment relative to controls and after consultation with the Data and Safety Monitoring Board elected to stop enrollment of the study.

Bradford A. Zakes, President and CEO stated, "Although we would have preferred to obtain more efficacy and safety data at higher doses of microbubbles, we were encouraged by the data from the first cohort of patients. One vial of MRX-801 in combination with ultrasound and tPA did not result in any reported cases of intracranial hemorrhage in the treatment group, suggesting a safe dose for further clinical studies. Furthermore, an analysis of activity from the first cohort indicated a trend

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
(Date:10/8/2015)... -- The 2015 Nobel Prize in Chemistry has been ... Aziz Sancar , who earned his PhD in molecular ... 1977, is one of three scientists who received the Nobel Prize ... DNA on a molecular level.  --> Aziz Sancar , ... Dallas in 1977, is one of three ...
(Date:10/8/2015)... 2015  Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... within its Applied Diagnostics and Testing business segment ... product line with ten certified Snap-N-Spike ® ... and their stable-labeled internal standards. These new solution ... taurocholic acid and native and deuterium-labeled analogs of ...
(Date:10/7/2015)... Mass. , Oct. 7, 2015 ... announced the start of the Boston Scientific Connected ... encourage advancements in the use of remote patient monitoring ... engineers, designers and entrepreneurs can submit their ideas and ... site ( ). Cambridge, MA ...
(Date:10/7/2015)... , Oct. 7, 2015   PDI , ... released an infographic that highlights key challenges across various ... appropriate disinfectant for the situation. This tool is part ... hospitals can take to create efficiencies and lower healthcare-associated ... The visual guide emphasizes examples of how to use ...
Breaking Biology Technology:
... Feb. 7 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) ... Access, is scheduled to deliver a presentation about the ... on February 13, 2008 at,12:30 pm Eastern Time. The ... City at the Waldorf Astoria Hotel., The presentation ...
... 7 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... results, for the quarter ended December,31, 2007, on February ... the earnings and to give a corporate update., ... and Chief Executive,Officer, and Craig W. Carlson, Vice President ...
... -- Total segment operating profit increased 77% when compared to the same ... posting 14% volume growth in the quarter, -- Fertilizer continued ... Financial Highlights (In millions, except per share data and percentages), ... Quarter Ended ...
Cached Biology Technology:
(Date:9/29/2015)... MILWAUKEE , Sept. 29, 2015  iDAvatars is excited ... partners to introduce its product to market. The official announcement was ... Cognitive Economy event in San Francisco ... Avatar platform powered by IBM Watson. "It is ... the first 100 companies to bring to market the cognitive ...
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... LONDON , Sept. 10, 2015 ... This New Study Reveals Selling Opportunities and Revenue ... What,s the future of biologics, especially new drug ... You will stay ahead with exclusive market data ... can explore trends, developments, results, opportunities and sales ...
Breaking Biology News(10 mins):
... multi-national research team led by scientists at Duke-NUS Graduate ... fail to respond to some of the most successful ... effectively in most patients to fight certain blood cell ... lung cancers (NSCLC) with mutations in the EGFR gene. ...
... ago preceded the oxygenation of our planet and the ... has shown. , Research, led by experts at Newcastle ... Nature Geoscience , reveals that the Earth,s early atmosphere ... state similar to that of Saturn,s moon, Titan. , ...
... holds the human world record for the most densely populated ... the natural equivalent, the most species rich area on earth. ... Science , reveal the record is contested between South America,s ... large numbers of species in one space and the questions ...
Cached Biology News:
Parathyroid Hormone Receptor 2 [PTHR2]...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
Biology Products: